- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05847179
Vaihe 2, avoin tutkimus progeriniinin turvallisuuden ja siedettävyyden arvioimiseksi Wernerin oireyhtymässä
Vaihe 2, avoin tutkimus Progeriniinin turvallisuuden ja siedettävyyden arvioimiseksi luun mineraalitiheyden (BMD) menetyksen hoidossa potilailla, joilla on tyypillinen Werner-oireyhtymä
This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.
There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.
To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.
The secondary objectives of this study are:
- To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
- To evaluate vascular function in subjects with typical Werner Syndrome.
- To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
- To evaluate lipid metabolism in subjects with typical Werner Syndrome.
- To evaluate physical function in subjects with typical Werner Syndrome.
- To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Christine Lee
- Puhelinnumero: 301-540-2600
- Sähköposti: christinelee@kcrnresearch.com
Opiskelupaikat
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109
- Rekrytointi
- University of Michigan
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
[Inclusion Criteria]
-
Subjects must be at least ≥ 18 years of age.
-
Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.
-
Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.
-
Male or non-pregnant, non-lactating female.
-
Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.
-
Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.
Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.
Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.
-
Provide signed written informed consent and willingness, ability to comply with study requirements.
-
Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.
[Exclusion Criteria]
-
Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:
- Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
- Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
- Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
-
Subjects with significant dehydration as judged by the principal investigator.
-
Subjects with pericardial fluid, ascites and pleural effusion.
-
Therapy with investigational drugs within 30 days of beginning study medication.
-
History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.
-
Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.
-
Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).
-
Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).
-
Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.
-
Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).
-
Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.
-
Pregnant or lactating women.
-
Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.
-
Inability to return for scheduled treatment and assessments.
-
Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Treatment Group
all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year |
This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome. . There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
The intensity of the event will be graded using CTCAE v6.0 criteria |
Baseline to Week 56 (including 4-week follow-up)
|
|
Incidence of Treatment-Related Adverse Events
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of Serious Adverse Events (SAEs)
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Blood Chemistry from Baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Hematology from Baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Urinalysis Results from Baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Height (cm) from Baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Weight (kg) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Temperature (°C) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Pulse Rate (beats per minute) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Respiratory Rate (breaths per minute) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Systolic Blood pressure (mmHg) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Diastolic Blood pressure (mmHg) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Changes in Physical Examination findings from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG Ventricular Rate (beats per minute) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG PR interval (msec) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QRS interval (msec) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QT interval (msec) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
|
|
Change in ECG QTc interval (msec) from baseline
Aikaikkuna: Baseline to Week 56 (including 4-week follow-up)
|
Baseline to Week 56 (including 4-week follow-up)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Change in Femur Bone Mineral Density (BMD) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lumbar Spine BMD from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Lipid Profile from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Handgrip Strength Test from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Osteocalcin (OC) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Procollagen Peptides (P1NP) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in Deoxypyridinium (DPD) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Aikaikkuna: Baseline, Week 24, and Week 52
|
Baseline, Week 24, and Week 52
|
|
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Aikaikkuna: Baseline, Week12, Week 24, Week 36 and Week 52
|
Baseline, Week12, Week 24, Week 36 and Week 52
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- PRG-PRO-004
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .